Form 4: Nautilus Biotechnology Executive Acquires 160,000 Stock Options

Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024, according to a recent SEC filing.

Summary

• Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024.
• The exercise price of these options is $2.72.
• The options vest over time, with 25% vesting on January 1, 2025 (one year after the Vesting Commencement Date of January 1, 2024).
• The remaining options vest monthly thereafter, subject to Godwin's continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• The options expire on March 1, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of an executive stock option grant, with no inherent positive or negative implications.

Industry Context

This filing is a routine disclosure of stock option grants to a company executive, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The vesting schedule described (25% after one year, then monthly) is a typical vesting arrangement.
• Comparing the size of the grant to grants made to executives at similar-stage biotech companies (e.g., those with similar market capitalization and R&D spending) would provide further context.

Stakeholder Impact

• The stock option grant could incentivize the executive to improve company performance, potentially benefiting shareholders.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's outstanding shares.

Key Dates